EMAIL THIS PAGE TO A FRIEND

Neuropharmacology

Pharmacological characterization of GABAB receptor subtypes assembled with auxiliary KCTD subunits.


PMID 25196734

Abstract

GABAB receptors (GABABRs) are considered promising drug targets for the treatment of mental health disorders. GABABRs are obligate heteromers of principal GABAB1 and GABAB2 subunits. GABABRs can additionally associate with auxiliary KCTD8, 12, 12b and 16 subunits, which also bind the G-protein and differentially regulate G-protein signaling. It is unknown whether the KCTDs allosterically influence pharmacological properties of GABABRs. Here we show that KCTD8 and KCTD16 slightly but significantly increase GABA affinity at recombinant receptors. However, KCTDs clearly do not account for the 10-fold higher GABA affinity of native compared to recombinant GABABRs. The positive allosteric modulator (PAM) GS39783, which binds to GABAB2, increases both potency and efficacy of GABA-mediated G-protein activation ([(35)S]GTPγS binding, BRET between G-protein subunits), irrespective of whether KCTDs are present or not. Of note, the increase in efficacy was significantly larger in the presence of KCTD8, which likely is the consequence of a reduced tonic G-protein activation in the combined presence of KCTD8 and GABABRs. We recorded Kir3 currents to study the effects of GS39783 on receptor-activated G-protein βγ-signaling. In transfected CHO cells and cultured hippocampal neurons GS39783 increased Kir3 current amplitudes activated by 1 μM of baclofen in the absence and presence of KCTDs. Our data show that auxiliary KCTD subunits exert marginal allosteric influences on principal GABABR subunits. PAMs at principal subunits will therefore not be selective for receptor subtypes owing to KCTD subunits. However, PAMs can differentially modulate the responses of receptor subtypes because the KCTDs differentially regulate G-protein signaling.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B5399
(±)-Baclofen, ≥98% (TLC), solid
C10H12ClNO2
B0200000
Baclofen, European Pharmacopoeia (EP) Reference Standard
C10H12ClNO2
32900
Benalaxyl-M, PESTANAL®, analytical standard
C20H23NO3
B6768
Boric acid, BioReagent, for molecular biology, suitable for cell culture, suitable for plant cell culture, ≥99.5%
H3BO3
B7901
Boric acid, for electrophoresis, ≥99.5%
H3BO3
B2645
Boric acid, tablet, 1 g boric acid per tablet
H3BO3
202878
Boric acid, 99.999% trace metals basis
H3BO3
339067
Boric acid, 99.97% trace metals basis
H3BO3
B7660
Boric acid, BioXtra, ≥99.5%
H3BO3
B0394
Boric acid, ACS reagent, ≥99.5%
H3BO3
B0252
Boric acid, ReagentPlus®, ≥99.5%
H3BO3
15663
Boric acid, BioUltra, for molecular biology, ≥99.5% (T)
H3BO3
31146
Boric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., buffer substance, ≥99.8%
H3BO3
11607
Boric acid, puriss., meets analytical specification of Ph. Eur., BP, NF, 99.5-100.5%, powder
H3BO3
426148
Boric acid-11B, ≥99 atom % 11B
H311BO3
G6752
Guanosine, ≥98%
C10H13N5O5
G6264
Guanosine, suitable for cell culture, BioReagent
C10H13N5O5
75903
Guanosine, ≥97.0% (HPLC)
C10H13N5O5
339245
Hydrobromic acid, 48 wt. % in H2O, ≥99.99%
HBr
438065
Hydrobromic acid, ACS reagent, 48%
HBr
244260
Hydrobromic acid, ACS reagent, 48%
HBr
268003
Hydrobromic acid, reagent grade, 48%
HBr
18720
Hydrobromic acid solution, purum p.a., ≥62% (T)
HBr
18735
Hydrobromic acid solution, 33 wt. % in acetic acid
HBr
295418
Hydrogen bromide, ReagentPlus®, ≥99%
HBr
248630
Hydrogen bromide solution, 33 wt. % in acetic acid
HBr
P0380
L-Proline, ReagentPlus®, ≥99% (HPLC)
C5H9NO2
P5607
L-Proline, from non-animal source, meets EP, USP testing specifications, suitable for cell culture
C5H9NO2
P8865
L-Proline, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C5H9NO2
1568506
L-Proline, United States Pharmacopeia (USP) Reference Standard
C5H9NO2